Skip to main content

Market Overview

Adaptive Biotechnologies Secures FDA EUA For COVID-19 T-Cell Response Test


The FDA issued the Emergency Use Authorization (EUA) to Adaptive Biotechnologies Corp's (NASDAQ: ADPT) T-Detect COVID-19 Test on Friday. It will be used to determine whether an individual had been infected with SARS-CoV-2 in the past.

  • This T cell-based test is the first indication resulting from Adaptive's TCR-Antigen Map collaboration with Microsoft Corporation (NASDAQ: MSFT).
  • Unlike other tests that detect blood-based antibodies to determine the prior infection with the virus, the T-Detect COVID-19 Test leverages immune repertoire sequencing technology to identify individuals with an adaptive T-cell response to SARS-CoV-2, indicating recent or prior infection.
  • The EUA was issued based on a clinical validation study demonstrating a sensitivity of 97.1% from the date of COVID-19 diagnosis with RT-PCR. The test also showed a specificity of 100%.
  • The FDA noted that the test should not be used to diagnose current SARS-CoV-2 infection.
  • The blood-based test is for use by healthcare professionals on samples from individuals who experienced COVID-19 symptoms at least 15 days earlier, the FDA said. 
  • Price Action: ADPT shares are up 15.7% at $48.84 in the premarket session on the last check Monday.

Related Articles (MSFT + ADPT)

View Comments and Join the Discussion!

Posted-In: Covid-19Biotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at